Suscribirse

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study - 27/03/20

Doi : 10.1016/S1473-3099(20)30086-4 
Heshui Shi, MD a, b, *, Xiaoyu Han, MD a, b, *, Nanchuan Jiang, MD a, b, *, Yukun Cao, MD a, b, Osamah Alwalid, MD a, b, Jin Gu, MD a, b, Yanqing Fan, MD c, , , Chuansheng Zheng, ProfMD a, b, ,
a Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China 
b Hubei Province Key Laboratory of Molecular Imaging, Wuhan, Hubei, China 
c Department of Radiology, Wuhan Jinyintan Hospital, Wuhan, Hubei, China 

* Correspondence to: Dr Yanqing Fan, Department of Radiology, Wuhan Jinyintan Hospital, Wuhan, Hubei 430022, China Department of Radiology Wuhan Jinyintan Hospital Wuhan Hubei 430022 China ** Prof Chuansheng Zheng, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China Department of Radiology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Background

A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were successively reported in Wuhan, China. We aimed to describe the CT findings across different timepoints throughout the disease course.

Methods

Patients with COVID-19 pneumonia (confirmed by next-generation sequencing or RT-PCR) who were admitted to one of two hospitals in Wuhan and who underwent serial chest CT scans were retrospectively enrolled. Patients were grouped on the basis of the interval between symptom onset and the first CT scan: group 1 (subclinical patients; scans done before symptom onset), group 2 (scans done ≤1 week after symptom onset), group 3 (>1 week to 2 weeks), and group 4 (>2 weeks to 3 weeks). Imaging features and their distribution were analysed and compared across the four groups.

Findings

81 patients admitted to hospital between Dec 20, 2019, and Jan 23, 2020, were retrospectively enrolled. The cohort included 42 (52%) men and 39 (48%) women, and the mean age was 49·5 years (SD 11·0). The mean number of involved lung segments was 10·5 (SD 6·4) overall, 2·8 (3·3) in group 1, 11·1 (5·4) in group 2, 13·0 (5·7) in group 3, and 12·1 (5·9) in group 4. The predominant pattern of abnormality observed was bilateral (64 [79%] patients), peripheral (44 [54%]), ill-defined (66 [81%]), and ground-glass opacification (53 [65%]), mainly involving the right lower lobes (225 [27%] of 849 affected segments). In group 1 (n=15), the predominant pattern was unilateral (nine [60%]) and multifocal (eight [53%]) ground-glass opacities (14 [93%]). Lesions quickly evolved to bilateral (19 [90%]), diffuse (11 [52%]) ground-glass opacity predominance (17 [81%]) in group 2 (n=21). Thereafter, the prevalence of ground-glass opacities continued to decrease (17 [57%] of 30 patients in group 3, and five [33%] of 15 in group 4), and consolidation and mixed patterns became more frequent (12 [40%] in group 3, eight [53%] in group 4).

Interpretation

COVID-19 pneumonia manifests with chest CT imaging abnormalities, even in asymptomatic patients, with rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progressed to or co-existed with consolidations within 1–3 weeks. Combining assessment of imaging features with clinical and laboratory findings could facilitate early diagnosis of COVID-19 pneumonia.

Funding

None.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2020  Elsevier Ltd. Reservados todos los derechos.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 20 - N° 4

P. 425-434 - avril 2020 Regresar al número
Artículo precedente Artículo precedente
  • A love letter for my father
  • Marco De Ambrogi
| Artículo siguiente Artículo siguiente
  • Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study
  • David Liebowitz, Keith Gottlieb, Nikita S Kolhatkar, Shaily J Garg, Jason M Asher, Jonathan Nazareno, Kenneth Kim, David R McIlwain, Sean N Tucker